Sponsor Overview
Explore verified public information about Imaging Biometrics, LLC's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Imaging Biometrics is proud to announce that we have secured approval from the FDA for an Expanded Access Program (EAP). The EAP is open to physicians whose patients have exhausted standard-of-care therapies and fit the eligibility criteria. This program is a beacon of hope for individuals in the United States battling brain tumors who were unable to partake in our initial clinical trial at MCW.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Glioblastoma, Refractory Glioblastoma, Glioblastoma Multiforme
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria We are considering an intermediate group EAP.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.